Interleukin-23 as a Predictor of Activities in Inflammatory Bowel Disease
نویسندگان
چکیده
منابع مشابه
Polymorphisms of interleukin-23 receptor in patients with inflammatory bowel disease in a Croatian tertiary center.
The Interleukin-23 signalling pathway is important for the differentiation of TH17 lymphocytes and is involved in the pathogenesis of Inflammatory bowel disease. Polymorphisms in the IL-23 receptor gene were previously found to be associated with Inflammatory bowel disease in various populations. The aim of this study was to determine whether the specific rs11209026 and rs7530511 single-nucleot...
متن کاملSweet Syndrome Accompanying Inflammatory Bowel Disease in a Child
Acute neutrophilic dermatosis, first described in 1964 by Robert Douglas Sweet, is characterized by sudden onset fever, neutrophilic leukocytosis, and well demarcated erythematous papules, nodules, and plaques with dense neutrophilic infiltrates on histologic evaluation.Here is a report of a 7-year-old girl who presented with high grade fever, and discrete erythematous papular skin eruptions, w...
متن کاملEvaluation of Bcl2/BAX genes expression ratio as a marker of inflammatory bowel disease
Background: Apoptosis is an essential physiological process to maintain immune homeostasis. T-cell incorrect apoptosis appears to be involved in chronic inflammatory diseases such as inflammatory bowel disease (IBD). The aim of this study was to evaluate the Bcl2/BAX genes expression ratio in patients with IBD (Crohn’s disease and ulcerative colitis) compared to healthy persons. Materials and M...
متن کاملNeonatal Presentation of Unremitting Inflammatory Bowel Disease
Very-early-onset inflammatory bowel disease (VEO-IBD) has a distinct phenotype and should be considered a specific entity. VEO-IBD presents with very severe clinical pictures and is frequently known by an indeterminate colitis whose clinical remission is unmanageable. This study examines the case of a neonate with VEO-IBD, not responding to medical and surgical treatment. A 7-day-old Iranian fe...
متن کاملInhibition of Interleukin-12 and/or -23 for the Treatment of Inflammatory Bowel Disease.
BS A handful of agents have been, or are currently being, looked at as inhibitors of either interleukin (IL)-12 and -23 or just IL-23. Ustekinumab (Stelara, Janssen), which was recently approved by the US Food and Drug Administration (FDA) for the treatment of moderate to severe Crohn’s disease, is an antibody directed against the p40 subunit shared by IL-12 and -23. Thus, ustekinumab inhibits ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Egyptian Journal of Hospital Medicine
سال: 2023
ISSN: ['1687-2002', '2090-7125']
DOI: https://doi.org/10.21608/ejhm.2023.304058